• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G/A 1 ea172858-13ga2intra_hoth.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Hoth Therapeutics, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    44148G204

     

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 44148G204
     
     
     

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
     
     
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
     
     

     

    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    57,008

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    57,008

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person    57,008 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.2% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

     

    Page 2 of 6

     

     

    CUSIP No. 44148G204  

     

       
    1. Names of Reporting Persons.
       
     

    Daniel B. Asher

       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     United States of America
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    57,008

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    57,008

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person     57,008 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.2% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      IN; HC

      

    Page 3 of 6

     

     

    CUSIP No.

    44148G204

     

     

       
    1. Names of Reporting Persons.
       
     

    Intracoastal Capital LLC

       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a)
      (b)
       
       
    3. SEC Use Only
       
       
    4. Citizenship or Place of Organization     Delaware
       

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting Person
    With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power

    57,008

       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    57,008

     

       
    9. Aggregate Amount Beneficially Owned by Each Reporting Person     57,008 (see Item 4)
       
       
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
       
    11. Percent of Class Represented by Amount in Row (9)  4.2% (see Item 4)
       
       
    12. Type of Reporting Person (See Instructions)
       
      OO

      

    Page 4 of 6

     

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on January 13, 2021, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 11, 2022 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 2.

     

    (e) CUSIP Number

     

    44148G204

     

    Item 4. Ownership.

     

    (a) and (b):

     

    As of the close of business on December 31, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 57,008 shares of Common Stock, which consisted of (i) 16,502 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”) and (ii) 40,506 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 4.2% of the Common Stock, based on (1) 1,300,382 shares of Common Stock outstanding as of November 4, 2022, as reported by the Issuer, plus (2) 16,502 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 40,506 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:       0      .

     

    (ii) Shared power to vote or to direct the vote:       57,008      .

     

    (iii) Sole power to dispose or to direct the disposition of       0      .

     

    (iv) Shared power to dispose or to direct the disposition of       57,008      .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 8, 2023

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 6 of 6

     

    Get the next $HOTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/19/24 8:00:03 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

      NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement. On June 18, 2025, the Company received formal notice from the Nasdaq Listing Qualifications Department confirming that Hoth's common stock closed at or above the $1.00 minimum bid price for 10 consecutive trading sessions—from June  4th through June 17- satisfying the requirement under Listing Rule 5550(a)(2). As a result, the

      6/18/25 1:34:00 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

      HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing. Study Results: Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kgNo adverse effects on kidney, spleen, or thymus100% clean safety profile — no visible lesions or gross pathologyValidates safety of HT-KIT in vivoRobb Knie, CEO: "These results strengthen our confidence in HT-KIT as we advance toward clinical trials. A strong safety signal with dose responsiveness and no toxicity gi

      6/18/25 8:22:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics to Attend 2025 BIO International Convention

      NEW YORK, June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO International Convention, in Boston, MA, June 16-19,2025. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. To learn more about this event visit https://convention

      6/16/25 8:00:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care